Metalloproteinase inhibitor 1 (TIMP1)

Metalloproteinase inhibitor 1 (TIMP1) is a naturally occurring glycoprotein that functions as a primary endogenous regulator of matrix metalloproteinases (MMPs), which are enzymes responsible for degrading the extracellular matrix (UniProt, 2024). By forming non-covalent 1:1 complexes with the zinc-dependent catalytic sites of active MMPs, TIMP1 maintains the structural integrity of tissues and regulates processes such as wound healing and bone remodeling (NCBI Gene, 2023). In addition to its inhibitory role, TIMP1 exhibits pleiotropic effects, including the stimulation of cell proliferation and the inhibition of apoptosis via interactions with cell surface receptors like CD63 (PubMed, 2021). Pathologically, elevated TIMP1 levels are hallmark indicators of fibrosis and are frequently associated with poor prognosis in various cancers, where it can promote tumor growth and metastasis (StatPearls, 2023). While direct therapeutic targeting of TIMP1 has been explored through monoclonal antibodies and gene therapy, it is most widely utilized in clinical practice as a diagnostic biomarker, specifically as a component of the Enhanced Liver Fibrosis (ELF) score (PubMed, 2022). Pharmacological efforts to modulate the MMP/TIMP balance have historically utilized synthetic MMP inhibitors, although these often face challenges regarding selectivity and systemic toxicity (Journal of Clinical Investigation, 2020).

Other names

Tissue inhibitor of metalloproteinases 1TIMP-1Erythroid-potentiating activityEPAFibroblast collagenase inhibitorCollagenase inhibitor

Natural endogenous inhibition of zinc-dependent matrix metalloproteinases (MMPs) by binding to their catalytic site in a 1:1 stoichiometry, and independent signaling via CD63/integrin complexes.